Actoplus Met

indicated to support blood sugar regulation in patients with metabolic conditions.

Strengths: 500/15mg

Medicine details

Therapeutic class

Biguanide; Thiazolidinedione

Pharmacological class

Biguanide; Thiazolidinedione

Contraindications

diabetic ketoacidosis; severe renal impairment; heart failure

Minor side effects

nausea; diarrhoea

Moderate side effects

peripheral oedema; weight gain

Dosage forms

Film-coated tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

Takeda Pharmaceutical

Onset Time

1–2 weeks

Duration

24 hours

Storage instructions

Store below 25°C.

Drug interactions

alcohol; iodinated contrast agents

Age restrictions

Adult use only.

Pregnancy and breastfeeding

Pregnancy: Seek specialist advice. Breastfeeding: Not recommended.

Precautions and warnings

monitor liver function; regular glucose testing; observe for signs of bladder cancer

Serious side effects

lactic acidosis — requires immediate medical attention; heart failure — requires immediate medical attention

Patient summary

indicated to support blood sugar regulation in patients with metabolic conditions.

Mechanism of action

Metformin decreases glucose production in the liver and improves insulin sensitivity, while pioglitazone activates PPAR-gamma to increase cellular glucose uptake.

Actoplus Met

indicated to support blood sugar regulation in patients with metabolic conditions.

Editorial Notes

  • Active ingredient(s): Metformin, Pioglitazone
  • Listed indication(s): Type 2 Diabetes Mellitus

Available option

  • 90 tablets - 500/15 mg1047-500-15-mg-13195